The market for Lipid-Lowering Agents in Equatorial Guinea has been experiencing steady growth in recent years.
Customer preferences: There is a growing awareness among consumers in Equatorial Guinea about the importance of maintaining healthy cholesterol levels. This has led to an increased demand for Lipid-Lowering Agents, which are used to reduce cholesterol levels in the blood. Consumers are also becoming more health-conscious and are willing to invest in products that can help them maintain their overall health.
Trends in the market: One of the key trends in the Lipid-Lowering Agents market in Equatorial Guinea is the increasing availability of generic drugs. This has led to a reduction in prices and has made these drugs more affordable for consumers. Additionally, there has been a shift towards more natural and herbal remedies for reducing cholesterol levels. This is in line with the global trend towards natural and organic products.
Local special circumstances: Equatorial Guinea is a small country with a relatively small population. This means that the market for Lipid-Lowering Agents is also relatively small. However, there is a growing middle class in the country, which is driving demand for these products. Additionally, there is a high prevalence of cardiovascular disease in Equatorial Guinea, which is also contributing to the growth of the market for Lipid-Lowering Agents.
Underlying macroeconomic factors: Equatorial Guinea is a resource-rich country, with a significant oil and gas industry. However, the country has a high poverty rate and significant income inequality. This means that while there is a growing middle class, there are also many people who cannot afford to invest in healthcare products. Additionally, the country has a weak healthcare system, which means that many people do not have access to adequate healthcare services. This is driving demand for over-the-counter products such as Lipid-Lowering Agents.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
